[ad_1]
Durham, North Carolina, May 23, 2021 /PRNewswire/-Research is at Digestive System Disease Week (DDW) In 2021, the prevalence and predictive factors of immunomodulators used in combination with two commonly prescribed drugs vedolizumab (Entyvio) or ustekinumab (Stelara) in patients with inflammatory bowel disease (IBD) were assessed.Data from target RWE Target IBD Large vertical queue Immunomodulators are usually used in combination with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort Was selected as the Outstanding Poster Award.
In the past 30 years, the global prevalence of IBD has risen sharply.1 piece Biologics neutralize the proteins that cause inflammation in the body; however, not all biological agents act in the same way. Compared with anti-tumor necrosis factor drugs (anti-TNFs), newer biologics (such as ustekinumab and vedolizumab) are associated with a lower risk of infection. Adding immunomodulators to combination therapy may limit this potential benefit, especially in people over 65, without reducing immunogenicity.
Immunogenicity occurs when a therapy elicits an autoimmune response. This is a severe limitation of biological therapies used to treat inflammatory bowel diseases such as Crohn’s disease (CD) or ulcerative colitis (UC),” he said. Megan Lutz, MD, researcher University of Wisconsin School of Medicine As well as public health and the first author. “We need to further study the combination of immunomodulators and new biological therapies (such as ustekinumab or vedolizumab) to reduce the efficacy and safety of immunogenicity in patients with IBD, because we can avoid unnecessary risks caused by other generally safe treatment .”
The main findings include:
- Among the CD patients with vedolizumab or ustekinumab and the patients with vedolizumab UC at the time of enrollment, combination therapy accounted for 28.2% and 19.0%, respectively.
- The previous biological exposure rate was high: 73.8% of the patients treated with vedolizumab had received anti-TNF exposure, and 89.6% of the patients treated with ustizumab received anti-TNF exposure, of which 30.8% were also exposed Received vedolizumab exposure.
- Among CD patients who used ustekinumab on admission, combination therapy was more common in the community and in patients younger than 65 years of age.
A study conducted separately from TARGET-IBD, The TARGET-IBD real cohort study shows that patients with Crohn’s disease without biological knowledge are more likely to achieve mucosal healing than patients with rich biological experience, Found that consistent with the results of clinical trials, neonatal biological patients in the real-world CD cohort are more likely to achieve mucosal healing than patients with biological experience.
TARGET-IBD is a study of IBD patients receiving routine care in the American community and academic practice. It analyzes clinical data from secure electronic medical records to include patients July 2017 to November 2020.
About Target RWE
Target RWE is a health evidence solutions company that provides innovative real-world evidence (RWE) to healthcare partners. Target RWE’s novel NoviSci analysis platform can use the latest epidemiological methods and scientific principles to analyze and visualize health data, thereby providing a highly adaptable environment to accelerate insight and repeatable research.understand more www.targetrwe.com.
contact:
Kayla Slake
kslake@targetrwe.com
984.234.0268 ext. 205
View original content to download multimedia:http://www.prnewswire.com/news-releases/target-rwe-research-presented-at-ddw-2021-shows-high-rates-of-biologic-combination-therapy-and-previous-biologic-exposure- in-ibd-population-301297219.html
Source target RWE
[ad_2]
Source link
